Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial

By sjmartinez • May 15, 2024

Corado KC, Chew KW, Giganti MJ, Mu Y, Fletcher CV, Currier JS, Daar ES, Wohl DA, Li JZ, Moser CB, Ritz J, Javan AC, Neytman G, Caskey M, Hughes MD, Smith DM, Eron JJ; ACTIV-2/A5401 Study Team. Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial. Pathog Immun. 2024 May 6;9(1):138-155. doi: 10.20411/pai.v9i1.660. PMID: 38746756; PMCID: PMC11093219.

Tags: covid-19, Harbor UCLA, Infectious Diseases, Monoclonal antibodies, outpatient treatment, Publications, SARS-CoV-2, subcutaneous

Trimethylamine-N-oxide (TMAO) and risk of incident cardiovascular events in the multi ethnic study of Atherosclerosis

Budoff MJ, de Oliveira Otto MC, Li XS, Lee Y, Wang M, Lai HTM, Lemaitre RN, Pratt A, Tang WHW, Psaty BM, Siscovick DS, Hazen[...]

Characterizing the protective vasodilatory effects of hypobaric hypoxia on the neurovascular coupling response

Leacy JK, Burns DP, Jendzjowsky NG, Braun C, Herrington BA, Wilson RJ, Vermeulen TD, Foster GE, Rosenberg AJ, Anderson GK, Rickards CA, Lucking EF, O'Halloran[...]

Adhesin Als4112 promotes Candida auris skin colonization through interactions with keratinocytes and extracellular matrix proteins

Zhao G, Lyu J, Veniaminova NA, Zarnowski R, Mattos E, Johnson CJ, Quintanilla D, Hautau H, Hold LA, Xu B, Anku JAE, Dasgupta K, Hale[...]